The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.
All participants who are eligible and provide informed consent will complete an initial study visit, which includes a research blood collection and cognitive assessments. Depending on the results of the cognitive assessments, participants will complete follow-up visits annually or biennially for additional cognitive testing, research blood collections, and potential clinical testing for Alzheimer's disease as determined by the participant's medical provider.
Study Type
OBSERVATIONAL
Enrollment
1,800
Tau PET (flortaucipir)
Amyloid PET (florbetapir), CSF amyloid test, or blood amyloid test
Research blood assays for amyloid, tau, and neurodegeneration
Washington University School of Medicine
St Louis, Missouri, United States
RECRUITINGArea under the curve (AUC) of plasma amyloid-beta 42/40 in predicting amyloid PET status
Time frame: Baseline
Area under the curve (AUC) of plasma %p-tau217 in predicting amyloid PET status
Time frame: Baseline
Area under the curve (AUC) of plasma p-tau217 in predicting tau PET status
Time frame: Baseline
Area under the curve (AUC) of plasma %p-tau217 in predicting clinical diagnosis
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years
Area under the curve (AUC) of plasma amyloid-beta 42/40 in predicting clinical diagnosis
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years
Area under the curve (AUC) of plasma p-tau205 in predicting tau PET status
Time frame: Baseline
Area under the curve (AUC) of plasma neurofilament light in predicting tau PET status
Time frame: Baseline
Area under the curve (AUC) of plasma %p-tau205 in predicting clinical diagnosis
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years
Area under the curve (AUC) of plasma neurofilament light in predicting clinical diagnosis
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years
Area under the curve (AUC) of plasma eMTBR-243 in predicting tau PET status
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinical Dementia Rating (CDR) or electronic Clinical Dementia Rating (eCDR); Montreal Cognitive Assessment (MoCA)
Time frame: Baseline
Area under the curve (AUC) of plasma eMTBR-243 in predicting clinical diagnosis
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years